Company
AbbVie
Official Name: AbbVie Inc.
Headquarters: North Chicago, IL, United States
Founded: 2013
Employees: 50,000
CEO: Mr. Richard A. Gonzalez
Market Cap
$239.18 Billion
USD as of July 1, 2023
Company Description
AbbVie Inc. is a pharmaceutical company. It is dedicated to the research and development, manufacturing, and marketing of medicine for a number of chronic diseases including autoimmune diseases, leukemia, lymphoma, hepatitis C, and HIV. It is also engaged in the treatment of pancreatic, thyroidal, and other hormonal insufficiencies.
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—General
| Company | Market Cap (USD) |
|---|---|
Lilly
|
$417.05 B |
|
Johnson & Johnson
|
$412.24 B |
|
Merck
|
$275.82 B |
Roche
|
$241.08 B |
AstraZeneca
|
$224.80 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
|
UnitedHealth Group
|
$428.70 B |
|
Lilly
|
$417.05 B |
|
Johnson & Johnson
|
$412.24 B |
Novo Nordisk
|
$329.83 B |
|
Merck
|
$275.82 B |
Detailed Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Unlock the Power of Financial AI:
Try Disfold AI Free for 7 Days!
Stocks & Indices
AbbVie Inc. has the following listings and related stock indices.
Stock: NYSE: ABBV wb_incandescent
Stock: BCBA: ABBV wb_incandescent
Stock: BMV: ABBV wb_incandescent
Stock: Bovespa: ABBV34 wb_incandescent
Stock: FSX: 4AB wb_incandescent
Stock: MTA: 4AB wb_incandescent
Product & Services
Pharmaceutical drugsHumira (adalimumab)Imbruvica (ibrutinib)Venclexta (venetoclax)Zinbryta (daclizumab)Kaletra (lopinavir)Norvir (ritonavir)Mavyret/Maviret (glecaprevir/pibrentasvir)Skyrizi (risankizumab)
Key People
Richard A. Gonzalez (Chairman and CEO) Michael Severino (Vice Chairman and President)
Financials
Revenue: US$56.197 billion (2021)
Operating income: US$17.924 billion (2021)
Net income: US$11.542 billion (2021)
Total assets: US$150.565 billion (2020)
Total equity: US$13.097 billion (2020)